BACKGROUND AND OBJECTIVE

COVID-19 pandemic gave rise to an increase in demand for pneumococcal and influenza vaccines. Several approaches to improve vaccination rates among different populations were investigated to address this need. Social media may be used as a platform to promote and improve vaccination rates. The study aimed to determine the effect of social media promotion, on the number of patients requesting vaccination in a government tertiary hospital.

The study was conducted using a quasi-experimental design. A telehealth-based vaccination delivery system was established. The need for vaccination against flu and pneumonia was then promoted on a social media platform during the first month of the study. Posters on the risk of not being vaccinated and safety profile of vaccines were added on the second month. The number of requests for vaccination for each month was compared. Social media metrics of the two months of the study were likewise described.

A total of 23 requests for vaccination were recorded, 11 on the first month and 12 on the second month. When a boost in advertising for the posts was implemented, twice as many requests were made during the third week of the second month as compared to the previous month (5 vs 10). Social media promotion with poster showed higher average in reach, engagement and comments per week than without poster. The mean differences among the social media metrics, however, were not statistically significant.

Promotion with posters resulted in a slight increase in number of vaccination requests. Further increase in requests may require a more refined social media promotional strategy.

The 7-valent pneumococcal protein conjugate vaccine (PCV7) has been shown to be highly efficacious against invasive pneumococcal diseases and effective against pneumonia and in reducing otitis media. The introduction of PCV7 has resulted in major changes in the epidemiology of pneumococcal diseases. However, pneumococcal vaccines induce serotype-specific immunity, and a relative increase in non-vaccine serotypes has been reported following the widespread use of PCV7, leading to a need for extended serotype coverage for protection. PCV10 and PCV13 have been licensed on the basis of noninferiority of immunogenicity compared to a licensed conjugate vaccine. In this article, we aimed to review important data regarding the efficacy and effectiveness of the extended-coverage PCVs published or reported thus far and to discuss future implications for pneumococcal vaccines in Korea. After the introduction of PCV10 and PCV13, within a short period of time, evidence of protection conferred by these vaccines against invasive and mucosal infections caused by most of the serotypes included in the vaccines is accumulating. The choice of vaccine should be based on the changes in the dynamics of pneumococcal serotype distribution and diseases in the region where the vaccines are to be used. Continuous surveillance is essential for the appropriate use of pneumococcal vaccines and evaluation of the impact of PCVs on pneumococcal diseases.
Epidemiology ; Korea ; Otitis Media ; Pneumococcal Vaccines ; Pneumonia ; Vaccines ; Vaccines, Conjugate*

BACKGROUND

A community survey on the immunization status of residents in Barangay Pinag-Isang Palad, Old Balara, Quezon City, reflected a low immunization rate of 8% for influenza and 6% for pneumococcal vaccines. Exploring ways to increase awareness on vaccination is important to improve the delivery of primary prevention.

This study aimed to compare the effectiveness of infomercials versus infographics in promoting influenza and pneumococcal vaccination among residents of Barangay Pinag-Isang Palad.

A quasi-experimental study design using systematic sampling where one group of respondents was assigned to the infomercial intervention, and the other group to the infographics intervention. Each participant completed a self-administered 25-item questionnaire assessing perceived barriers to influenza and pneumococcal vaccination. Wilcoxon signed rank test was used to compare within group changes in scores pre- and post-intervention. Mann-Whitney test was used to determine between group differences in post-intervention scores.

A total of 70 respondents representing 70 households in the barangay participated in the study. Respondents were mostly from the 26-35 age group, females with high school education in the service industry, with < P23,381 average monthly income, and good self-reported health status. Comparison of the pre- and post-intervention mean scores of both groups (infomercial and infographics), showed statistically significant change in post-intervention mean scores from baseline. However, comparison of the post-intervention mean scores between groups was not statistically significant. Identified barriers in both groups were challenges in affordability and accessibility of influenza and pneumococcal vaccines.

This study showed that the InfoVax Strategy, using infomercials and infographics, can be effective tools in improving perceptions on influenza and pneumococcal vaccination among residents of Barangay Pinag-Isang Palad. The findings of this study can be applied to communities having similar characteristics. Healthcare providers may improve perceptions on vaccination and subsequent uptake by distributing infographics or playing infomercials aside from public health lectures. Vaccination will help prevent loss of earnings and incrased medication consumption. The local health unit needs to evaluate and address the identified barriers of affordability and accessibility.

Pneumococcal disease is a serious global public health problem and a leading cause of morbidity and mortality of children and adults in China. Antibiotics are commonly used to treat pneumococcal disease. However, antibiotic resistance to
Adult ; Child ; China ; Consensus ; Humans ; Pneumococcal Infections/prevention & control* ; Pneumococcal Vaccines ; Streptococcus pneumoniae ; Vaccines, Conjugate

Streptococcus pneumoniae (pneumococcus) is an important pathogen with high morbidity and mortality worldwide. Pneumococcal vaccine is an important measure to reduce the pneumococcal disease burden. Currently, two pneumococcal vaccines are available in adults, including 23-valent pneumococcal polysaccharide vaccine (PPV23) and 13-valent pneumococcal protein-conjugate vaccine (PCV13). PCV13 consists of capsular polysaccharides derived from the 13 most common types that cause invasive diseases (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, and 23F). PPV23 covers 10 additional serotypes compared to PCV13, but it does not include serotype 6A. Even though limited in the number of serotypes, PCV13 has several important advantages over PPV23: T-cell dependent superior immunogenicity, booster effect, absence of hypo-responsiveness and protective effect on pneumonia. Although PPV23 is effective to prevent 50% to 80% of invasive pneumococcal diseases, it may be ineffective for high-risk immunocompetent and immunocompromised patients. In adults, the choice of pneumococcal vaccine should be based on the severity of underlying medical conditions and local serotype distribution. Serotype distribution is quite variable temporally and geographically. Continuous sero-surveillance is essential for the establishment of optimal vaccination strategy.
Adult ; Humans ; Immunocompromised Host ; Mortality ; Pneumococcal Infections ; Pneumococcal Vaccines ; Pneumonia ; Polysaccharides ; Streptococcus pneumoniae ; T-Lymphocytes ; Vaccination

Child ; Drug Resistance, Bacterial ; Humans ; Pneumococcal Infections ; drug therapy ; prevention & control ; Pneumococcal Vaccines ; immunology

Humans ; Pneumococcal Infections ; prevention & control ; Pneumococcal Vaccines ; therapeutic use ; Practice Guidelines as Topic

More than 100 serotypes of Streptococcus pneumonia have been identified, which has been one bottleneck problem for pneumococcal disease diagnosis, surveillance, development of pneumococcal vaccine and effectiveness evaluation of pneumococcal vaccines. Three categories of approaches for pneumococcal serotyping will be discussed including phenotyping based on anti-serum, biochemical typing based on pneumococcal capsular characteristics and genotyping based on pneumococcal capsular locus sequences. We reviewed the development and applications of different serotyping of pneumococcus to provide guidance for pneumococcal disease prevention and control.
Humans ; Serotyping/methods* ; Pneumococcal Infections/prevention & control* ; Pneumococcal Vaccines ; Streptococcus pneumoniae/genetics* ; Pneumonia

This study systematically retrieved information on the payment policy of vaccination fees for pneumococcal vaccines, human papillomavirus vaccines, haemophilus influenzae type b vaccines and rotavirus vaccines using a Python-based crawler. The proportion of the population covered by policies among the total applicable population was estimated based on the medical insurance coverage ratio and population data in 2020. This study showed that the payment policies included two categories, government-funded free vaccination policies and medical insurance payment policies. Among the four non-national immunization program vaccines, the free vaccination policies only involved pneumococcal vaccines and human papillomavirus vaccines. Among them, the 13-valent pneumococcal conjugate vaccine, the 23-valent pneumococcal polysaccharide vaccine, and the human papillomavirus vaccine were provided free of charge in 1, 10 and 15 provinces, respectively. For these policies, the corresponding covered population and the proportion among the total applicable population were children aged 6 months to 2 years old (2.5%), older people (1.2% to 21.5%) and middle school girls (1.1% to 12.2%). Medical insurance payment policies were implemented in 14 provinces, and nearly covered the four types of vaccines in the policy implementation areas, with the proportion of the covered population about 10.9% to 41.5% among the total applicable population.
Child ; Female ; Humans ; Infant ; Aged ; Pneumococcal Vaccines ; Vaccination ; Policy ; Immunization Programs ; Papillomavirus Vaccines ; China ; Vaccines, Conjugate

This study systematically retrieved information on the payment policy of vaccination fees for pneumococcal vaccines, human papillomavirus vaccines, haemophilus influenzae type b vaccines and rotavirus vaccines using a Python-based crawler. The proportion of the population covered by policies among the total applicable population was estimated based on the medical insurance coverage ratio and population data in 2020. This study showed that the payment policies included two categories, government-funded free vaccination policies and medical insurance payment policies. Among the four non-national immunization program vaccines, the free vaccination policies only involved pneumococcal vaccines and human papillomavirus vaccines. Among them, the 13-valent pneumococcal conjugate vaccine, the 23-valent pneumococcal polysaccharide vaccine, and the human papillomavirus vaccine were provided free of charge in 1, 10 and 15 provinces, respectively. For these policies, the corresponding covered population and the proportion among the total applicable population were children aged 6 months to 2 years old (2.5%), older people (1.2% to 21.5%) and middle school girls (1.1% to 12.2%). Medical insurance payment policies were implemented in 14 provinces, and nearly covered the four types of vaccines in the policy implementation areas, with the proportion of the covered population about 10.9% to 41.5% among the total applicable population.
Child ; Female ; Humans ; Infant ; Aged ; Pneumococcal Vaccines ; Vaccination ; Policy ; Immunization Programs ; Papillomavirus Vaccines ; China ; Vaccines, Conjugate